Momentum leaders · current
US momentum leaders — August 2026
As of 25 August 2026
August's leaders are topped by RFAI (score 377.4, +377.0% over one month on +380.4% over three), a Financial Services name, followed by MRNA (+182.3% 1m, +234.0% 3m) and ARCT (+168.7% 1m, +114.6% 3m). Healthcare carries most of the rest of the list — OABI (+129.6% 1m), AMLX (+91.8% 1m on +173.2% 3m), HELP (+81.3% 1m on +215.1% 3m), TWST (+74.5% 1m) — with EDRY (+114.7% 1m, Industrials) and TEAM (+73.6% 1m,…
Near-total redemption — 3,956,323 of 3,998,108 public shares, 98.95% — left almost no tradable float into the 2026-08-19 Nanyang Biologics…
First-ever positive Phase 3 for an mRNA cancer therapy (INTerpath-001, 2026-08-19) re-rated MRNA 177.0% in one session to $174.38 and swapped the…
CSL exit hands back global KOSTAIVE plus flu/RSV/EBV rights, $12M cash and ~$16M of released liabilities, against $191.5M cash and runway guided…
Milestone-and-royalty flywheel turned visible: Q2 revenue $13.415M vs $4.693M consensus (2026-08-06) plus a Lilly ion-channel deal worth up to…
Dry-bulk operating leverage ran ahead of its own driver: EDRY closed at a 52-week high $46.85 on 2026-08-21 with RSI(14) 91.2, while the BDI sat…
AI coronary diagnostics re-rated on the 2026-08-13 Q2 print: revenue +48% YoY to $64.1M, FY26 guide lifted to $246–250M from $228–232M, Plaque…
Single-asset binary, now inside the guided window: Amylyx reaffirmed on 2026-08-06 that Phase 3 LUCIDITY topline for avexitide in post-bariatric…
Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back…
Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a…
The gamma-squeeze/index leg is over: PURR is -42% from its 6/1 high of $11.62 to $6.68 (7/17), through the $7.70 shelf, and now trades at roughly…
Oncology molecular-profiling re-rate: the 2026-08-05 Q2 beat ($263.7M vs $238.1M est) plus an FY26 guide lift to $1.030–1.040B and positive…
Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since…
Treasury-premium narrative still inverted: the 2026-08-10 Q2 print booked a $257.6M loss, 94.1% mark-to-market, against a $94,761 average cost…
The "agentic AI kills seat-based software" de-rating just reversed: Q4 FY26 (2026-08-06) put cloud +31% and $6,606M subscription ARR behind the…
Beat-and-raise on 2026-08-10 flipped the frame: Q2 adjusted EBITDA margin 23.3% (vs 21.0% in Q1), FY26 adjusted EPS guided up to $1.08–1.12, net…
Autoimmune-diagnostics re-rating on the 2026-08-04 Q2 print: revenue $19.941M vs $17.817M consensus, FY26 guide lifted to $72–75M, adjusted EBITDA…
The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand…
Post-print launch-ramp narrative still accelerating on fundamentals — Q2 net sales $28.5M vs $12.7M consensus (2026-08-12), NTAP effective…
Single-asset CAR-T regulatory story: NXC-201 posted a 95% CR rate (19/20) in NEXICART-2 on 2026-05-21 and holds FDA Breakthrough Therapy…
Signed all-cash takeout: Teledyne agreed on 2026-08-10 to buy Varex at $18.90/share (~$1.1B). The 2026-08-14 close of $18.49 leaves roughly $0.41…
Gold/copper producer basing $53–$76 under a broken ~$72 shelf after a ~45% fall from the $110 high. Q2 output slipped 8% QoQ — first sequential…
Corporate re-rating from the 2026-07-27 Sweetwater close is now fully priced-in news; RSI(14) 79.9 on 2026-08-21 with no company headline since…
Commercial-execution re-rating still working on no new information: after the 2026-08-03 guidance raise to $140–150M and the 2026-08-11 Q2 beat…
Not a growth story — a cash-deal spread. Bernhard Capital's $43.00 all-cash take-private (signed 2026-08-10) caps the name; the 2026-08-21 close…
Second-order re-rating: Merck/Moderna's 2026-08-19 Phase 3 INTerpath-001 win — the first positive readout for an individualised neoantigen therapy…
Guidance-raise leg intact but the flow has thinned: no company datapoint since the 2026-08-05 print (rev $28.252M +48.1%, FY26 lifted to…
Silver-zinc producer re-rating: Nasdaq debut 2026-01-21, Glencore's US$40M base price cleared October 2025, Q1 2026 revenue $127.5M (+81% YoY), Q2…
Hypergrowth brokerage story has decelerated (Q1 rev +32% vs 70%+ historically, a forecast miss) and the stock sits near 52-week lows after the…
Cloud-genomics platform narrative inflected on the 2026-08-04 Q2 print: net dollar retention 117% vs 107% YoY, FY26 guide raised to $94–96M, and a…
Gold-miner margin leverage at a fresh high: spot $4,607/oz on 2026-08-21 (+11.54% MoM) turned Q2 free cash flow to $727M and the balance sheet to…
Operating-leverage re-rating on a de-rated HCM name is still working, but the fuel is two weeks stale: since the 2026-08-06/07 target raises the…
Second-order agentic-AI re-rating has extended past the print without new numbers: after the 2026-08-06 beat and FY26 raise to $845–853M, price…
Gold-equity operating leverage re-accelerating: spot gold ran from clearing $4,200 on 2026-08-05 to $4,577.49 on 2026-08-21, and Agnico's TTM net…
Critical-minerals refining narrative still producing dated milestones — $25M Department of War investment 2026-07-14, first commercial-scale…
Copper-squeeze beta finally re-rated: the 2026-08-21 close of $39.42 is a new 52-week high (RSI 78.1, +46.1% over three months) clearing the prior…
Post-divestiture handheld chemical-detection pure play re-rating on the 2026-08-11 beat-and-raise (revenue $16.07M vs $15.37M est, FY floor lifted…
Base44 margin inversion is the live leg and the market is now paying up for it: after the 2026-08-04 beat ($563.1M, +15%; adj EPS $1.39 vs $1.16)…
Wet-AMD one-and-done durability narrative accelerating on the 2026-07-18 PRISM 2-year data (78% injection-burden reduction, 2.7 vs 12.0 projected,…
Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19%…
Post-print re-rate extending: 2026-08-21 close $13.29 is 0.1% under the 52-week high after a 98.4% three-month move, with Morgan Stanley to $16…
Deleveraging leg is holding but no longer advancing: the 2026-08-06 10-Q showed H1 operating cash flow of $68.9M against capex of just $15.9M (vs…
Growth re-acceleration re-rated the name on the 2026-08-06 Q2 print (revenue +28.8% to $196.6M, FY2026 guide to $757.318M, buyback doubled to…
"3-mo price move" is the stock's market price change, not a FrontierPicks return.
How this board is built
Every name in the US equity universe is scored on a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closes and ranked highest-first. No model orders the board — the ranking is arithmetic. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. The board reflects price moves already made, not a forecast. Each covered name links to its dated research dossier — thesis, invalidation trigger, archetype and catalyst.
Questions
- What are the hottest US stocks right now?
- As of 25 August 2026, the US names with the strongest composite momentum score on FrontierPicks are RFAI, MRNA, ARCT, OABI. This is a momentum ranking of price moves already made — research, not advice.
- How is this momentum ranking built?
- Every name in the US equity universe is scored on a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closes, then ranked highest-first. The arithmetic is the whole ranking — no model orders the board. Each covered name links to its dated research dossier. Methodology is open.
- Is a high ranking a recommendation?
- No. The board reflects price moves that have already happened, not a forecast or a recommendation. It is educational research, not investment advice.
As of 25 August 2026 · research, not advice.